tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Promising Pipeline Developments Drive Buy Rating for CAMP4 Therapeutics
PremiumRatingsPromising Pipeline Developments Drive Buy Rating for CAMP4 Therapeutics
1M ago
Promising Potential and Strategic Growth: Buy Rating for CAMP4 Therapeutics
Premium
Ratings
Promising Potential and Strategic Growth: Buy Rating for CAMP4 Therapeutics
1M ago
Camp4 Therapeutics reports Q2 EPS (62c), consensus (67c)
Premium
The Fly
Camp4 Therapeutics reports Q2 EPS (62c), consensus (67c)
1M ago
Camp4 Therapeutics delivers three presentantions on SYNGAP1-related disorders
PremiumThe FlyCamp4 Therapeutics delivers three presentantions on SYNGAP1-related disorders
4M ago
CAMP4 Therapeutics: Promising Pipeline and Strong Financials Justify Buy Rating
Premium
Ratings
CAMP4 Therapeutics: Promising Pipeline and Strong Financials Justify Buy Rating
4M ago
Camp4 Therapeutics  reports Q1 EPS (62c), consensus (70c)
Premium
The Fly
Camp4 Therapeutics reports Q1 EPS (62c), consensus (70c)
4M ago
Camp4 Therapeutics sees  MAD safety and key biomarker data in 2H25
PremiumThe FlyCamp4 Therapeutics sees MAD safety and key biomarker data in 2H25
8M ago
Camp4 Therapeutics appoints Maraganore, Meyers are strategic advisors
Premium
The Fly
Camp4 Therapeutics appoints Maraganore, Meyers are strategic advisors
9M ago
CAMP4 Therapeutics Corp trading resumes
Premium
The Fly
CAMP4 Therapeutics Corp trading resumes
9M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100